Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire November 10, 2016

Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting

GlobeNewswire November 8, 2016

Syndax to Announce Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 10, 2016

GlobeNewswire October 28, 2016

Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences 

GlobeNewswire September 6, 2016

Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire August 9, 2016

Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)

GlobeNewswire July 27, 2016

Syndax to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9, 2016

GlobeNewswire July 20, 2016

Syndax Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

GlobeNewswire July 7, 2016

Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program

GlobeNewswire July 6, 2016

Syndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 14, 2016

Entinostat Data to be Highlighted at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

GlobeNewswire May 18, 2016

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

GlobeNewswire May 16, 2016

Syndax to Announce First Quarter 2016 Financial Results and Host Conference Call and Live Webcast on May 16, 2016

GlobeNewswire April 26, 2016

Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting

GlobeNewswire April 11, 2016

Nasdaq Welcomes Syndax Pharmaceuticals, Inc. to The Nasdaq Stock Market

GlobeNewswire March 3, 2016

Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO

GlobeNewswire March 3, 2016

Syndax Announces Pricing of Initial Public Offering

GlobeNewswire March 2, 2016